Mechanisms of diabetes mellitus induced with FK506 in SD rats models

References

• Antignac, M., Barrou, B., Farinotti, R., et al. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J. Clin. Pharmacol. 2007, 64(6),750–7.
   PubMedGoogle Scholar
• Blanchet, B., Duvoux, C., Costentin, C.E., et al. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period. Ther. Drug Monit. 2008, 30(4),412–8.
   PubMedGoogle Scholar
• Patel, J.K., Kobashigawa, J.A. Tacrolimus in heart transplant recipients: An overview. BioDrugs 2007, 21(3),139–43.
   PubMedGoogle Scholar
• Hachem, R.R., Yusen, R.D., Chakinala, M.M., et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J. Heart Lung Transplant. 2007, 26(10),1012–8.
   PubMedGoogle Scholar
• Rossetti, M., Piccoli, G.B., Burdese, M., et al. Tailored immunosuppression and steroid withdrawal in pancreas-kidney transplantation. Rev. Diabet. Stud. 2004, 1(3),129–36.
   PubMedGoogle Scholar
• Watts, A.B., Williams, R.O. 3rd., Peters, J.I. Recent developments in drug delivery to prolong allograft survival in lung transplant patients. Drug Dev. Ind. Pharm. 2008, 16,1–13.
   Google Scholar
• Kuypers, D.R. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf. 2005, 28(2),153–81.
   PubMedGoogle Scholar
• Chamienia, A., Biedunkiewicz, B., Król, E., et al. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus. Transplant Proc. 2006, 38(1),81–5.
   PubMedGoogle Scholar
• Nielsen, F.T., Leyssac, P.P., Kemp, E., et al. Nephrotoxity of FK 506: A preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity. Transplant Proc. 1994, 26(6),3104–5.
   PubMedGoogle Scholar
• Oztürk, S., Ayna, T.K., Cefle, K., et al. Effect of cyclosporin A and tacrolimus on sister chromatid exchange frequency in renal transplant patients. Genet. Test. 2008, 12(3),427–30.
   PubMedGoogle Scholar
• Vivarelli, M., Cucchetti, A., La Barba, G.,et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: Reassessment of risk factors for tumor recurrence. Ann. Surg. 2008, 248(5),857–62.
   PubMedGoogle Scholar
• Shimizu, T., Ishida, H., Shirakawa, H., et al. Clinical and histological analysis of chronic tacrolimus nephrotoxicity in renal allografts. Transplant Proc. 2008, 40(7),2370–2.
   PubMedGoogle Scholar
• Mazali, F.C., Lalli, C.A., Alves-Filho, G., et al. Posttransplant diabetes mellitus: Incidence and risk factors. Transplant Proc. 2008, 40(3),764–6.
   PubMedGoogle Scholar
• Sharma, A., Minz, M., Singh, S. et al. Incidence of glucose metabolic abnormalities in Indian living renal allograft recipients on tacrolimus-based triple drug immunosuppression. Transplant Proc. 2008, 40(7),2414–5.
   Google Scholar
• Uchizono, Y., Iwase, M., Nakamura, U., et al. Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling. Endocrinology 2004, 145(5),2264–72.
   PubMedGoogle Scholar
• Gelens, M.A., Christiaans, M.H., van Hooff, J.P., Glucose metabolism before and after conversion from cyclosporine microemulsion to tacrolimus in stable renal recipients. Nephrol. Dial. Transplant. 2008, 23(2),701–6. Epub 2007 No.
   PubMedGoogle Scholar
• Kanzler, S., Lohse, A.W., Schirmacher, P., et al. Complete reversal of FK 506 induced diabetes in a liver transplant recipient by change of immunosuppression to cyclosporine A. Z. Gastroenterol. 1996, 34(2),128–31.
   PubMedGoogle Scholar
• Bloom, R.D., Crutchlow, M.F. Transplant-associated hyperglycemia. Transplant Rev. (Orlando). 2008, 22(1),39–51.
   PubMedGoogle Scholar
• Christiansen, E. [Posttransplant diabetes. Metabolic consequences of posttransplant immunosuppressive treatment] Ugeskr Laeger. 2007, 169(24),2309–11.
   PubMedGoogle Scholar
• Dumler, F., Kilates, C. Metabolic and nutritional complications of renal transplantation. J. Ren. Nutr. 2007, 17(1),97–102.
   PubMedGoogle Scholar
• Mannon, R.B. Therapeutic management of posttransplant diabetes mellitus. Transplant Rev. (Orlando) 2008, 22(2),116–24.
   PubMedGoogle Scholar
• Salifu, M.O., Tedla, F., Aytug, S., et al. Posttransplant diabetes and hypertension: Pathophysiologic insights and therapeutic rationale. Curr. Diab. Rep. 2008, 8(3),221–7.
   PubMedGoogle Scholar
• Tuerk, T.R., Bandur, S., Nuernberger, J., et al. Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation. Clin. Nephrol. 2008, 70(1),26–32.
   PubMedGoogle Scholar
• Rodrigo, E., Fernández-Fresnedo, G., Valero, R., et al. New-onset diabetes after kidney transplantation: Risk factors. J. Am. Soc. Nephrol. 2006, 17(12 Suppl 3),S291–5.
   Google Scholar
• Chien, Y.S., Chen, Y.T., Chuang, C.H., et al. Incidence and risk factors of new-onset diabetes mellitus after renal transplantation. Transplant. Proc. 2008, 40(7),2409–11.
   PubMedGoogle Scholar
• Luan, F.L., Zhang, H., Schaubel, D.E., et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. Am. J. Transplant. 2008, 8(9),1871–7.
   PubMedGoogle Scholar
• Shehab-Eldin, W., Shoker, A. Predictors of new onset of diabetes after transplantation in stable renal recipients. Nephron. Clin. Pract. 2008,110(1),c1–9. Epub 2008 Jul 24.
   PubMedGoogle Scholar
• Veroux, M., Corona, D., Giuffrida, G., et al. New-onset diabetes mellitus after kidney transplantation: The role of immunosuppression. Transplant. Proc. 2008, 40(6),1885–7.
   PubMedGoogle Scholar
• Johnston, O., Rose, C.L., Webster, A.C., et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J. Am. Soc. Nephrol. 2008, 19(7),1411–8.
   PubMedGoogle Scholar
• Saboo, D., Shah, P.R., Goplani, K.R., et al. Posttransplant diabetes mellitus: A single-center study. Transplant. Proc. 2008, 40(4),1111–3.
   PubMedGoogle Scholar
• Marcén, R., Morales, J.M., del Castillo, D., et al. Posttransplant diabetes mellitus in renal allograft recipients: A prospective multicenter study at 2 years. Transplant. Proc. 2006, 38(10),3530–2.
   PubMedGoogle Scholar
• Sulanc, E., Lane, J.T., Puumala, S.E., et al. New-onset diabetes after kidney transplantation: An application of 2003 International Guidelines. Transplantation 2005, 15,80(7), 945–52.
   Google Scholar
• Wyzgał, J., Paczek, L., Sańko-Resmer, J., et al. Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors. Ann. Transplant. 2007, 12(2),26–9.
   PubMedGoogle Scholar
• Drachenberg, C.B., Klassen, D.K., et al. Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999, 68(3),396–402.
   PubMedGoogle Scholar
• Kohda, Y., Shirakawa, H., Yamane, K., et al. Prevention of incipient diabetic cardiomyopathy by high-dose thiamine. J. Toxicol. Sci. 2008, 33(4),459–72.
   PubMedGoogle Scholar